(Q33936179)

English

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

cholangiocarcinoma

0 references

intrahepatic cholangiocarcinoma

1 reference

based on heuristic

inferred from title

Nabeel Bardeesy

24

object named as

Nabeel Bardeesy

0 references

David C. Christiani

7

object named as

David C Christiani

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

28

object named as

Leif W Ellisen

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Darrell R Borger

1

object named as

Darrell R Borger

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

13

object named as

A John Iafrate

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

14

object named as

Eunice L Kwak

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jeffrey W Clark

15

object named as

Jeffrey W Clark

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

29

object named as

David P Ryan

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lawrence S Blaszkowsky

17

object named as

Lawrence S Blaszkowsky

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Theodore S Hong

20

object named as

Theodore S Hong

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Lipika Goyal

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Thomas Yau

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Ronnie T Poon

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Marek Ancukiewicz

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Vikram Deshpande

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Hannah M Liebman

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Hua Yang

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Hyeryun Kim

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Katharine Yen

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jason E Faris

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jill N Allen

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Janet E Murphy

18

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Supriya K Saha

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jennifer Y Wo

21

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Cristina R Ferrone

22

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Kenneth K Tanabe

23

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Nabeel Bardeesy

24

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Kimberly S Straley

25

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sam Agresta

26

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

David P Schenkein

27

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Andrew X Zhu

30

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

29 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1884-1890

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

IDH mutation impairs histone demethylation and results in a block to cell differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Genetics of biliary tract cancers and emerging targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

5 July 2018

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

29 October 2018

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

29 October 2018

2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

29 October 2018

Intrahepatic cholangiocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

29 October 2018

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

29 October 2018

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4107454

29 October 2018

Identifiers

10.1158/1078-0432.CCR-13-2649

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33936179&oldid=2081561842"